CMA issues revised guidelines on physicians' relationship with pharmaceutical industry

Williams, John R.
January 1994
CMAJ: Canadian Medical Association Journal;1/15/1994, Vol. 150 Issue 2, p263
Academic Journal
No abstract available.


Related Articles

  • Marketing Rx&D: the CMA president responds. Hanson, Dana // CMAJ: Canadian Medical Association Journal;5/13/2003, Vol. 168 Issue 10, p1274 

    Addresses a commentary on the role of the Canadian Medical Association (CMA) guidelines in the revision of the 2003 marketing practices of Rx&D, the think tank of Canada's pharmaceutical industry. Application of the CMA guidelines to continuing medical education; Focus of the commentary;...

  • Do Industry Ties Influence Patient Care Guidelines?  // Review of Optometry;3/15/2002, Vol. 139 Issue 3, p8 

    Investigates the relationships of physicians with pharmaceutical industry in relation to the writing of the patient care guidelines. Expansion of optometry practice; Influence of the relationship to the writing of the guidelines; Survey of the Journal of the American Medical Association...

  • PHYSICIANS AND THE PHARMACEUTICAL INDUSTRY (UPDATE 2001).  // CMAJ: Canadian Medical Association Journal;5/01/2001, Vol. 164 Issue 9, p1339 

    Presents guidelines by the Canadian Medical Association (CMA) to assist physicians in determining when a relationship with industry, particularly pharmaceutical companies, is appropriate. General principles for these relationships; Guidelines regarding industry-sponsored research and...

  • Physicians and the Pharmaceutical Industry.  // Annals of Internal Medicine;4/15/90, Vol. 112 Issue 8, p624 

    Addresses controversial issues related to the ethics of physician encounters with the pharmaceutical industry. Criterion for determining acceptable activities and relationships between physicians and the pharmaceutical industry; Reason behind the need for professional societies to develop...

  • Urologists: Most MDs know where to draw line on gifts. Nash, Karen // Urology Times;Nov2001, Vol. 29 Issue 11, p26 

    Focuses on the move of American Medical Association (AMA) to re-issue guidelines for the control of pharmaceutical products. Acceptance of pharmaceuticals and medical devices by physicians; Benefits of the physicians from pharmaceutical representatives; Impact of the AMA guidelines on...

  • New guidelines expected in 1991 for relationship of continuing education, financial support. Randall, Teri; Randall, T // JAMA: Journal of the American Medical Association;9/5/90, Vol. 264 Issue 9, p1080 

    Deals with a conference aimed at reaching a consensus on guidelines for an ethical relationship between the pharmaceutical industry and continuing medical education (CME) providers in the U.S. Questions on the credibility of CME programs; Concerns among physicians; Position statements issued by...

  • The costs of vilifying pharma. Collier, Roger // CMAJ: Canadian Medical Association Journal;9/8/2015, Vol. 187 Issue 12, pE369 

    The article tackles the costs of vilifying the pharmaceutical industry and the conflicts of interest in medical research. Topics discussed are the concern over the relationship of physicians with the pharmaceutical industry, the risk of anti-pharmaceutical bias among physicians and ways to...

  • Pharmaceutical industry and physician relationships explored: Part 2. Bal, B. Sonny; Brenner, Lawrence H. // Orthopedics Today;Dec2011, Vol. 31 Issue 12, p46 

    The article explores the issues associated with the invasion of the right of physicians and surgeons to make independent health care decisions, in relation to pharmaceutical industry-physician relationships.

  • A call for the regulation of prescription data mining. Zoutman, Dick E.; Ford, B. Douglas; Bassili, Assil R. // CMAJ: Canadian Medical Association Journal;10/31/2000, Vol. 163 Issue 9, p1146 

    Focuses on the debate surrounding prescription data mining practices in Canada. Details of Canadian Medical Association (CMA) guidelines regarding the sale and use of physicians' prescribing data; Role of the IMS Canada corporation in the sale of prescription data to the pharmaceutical...

  • A lot to be proud of. Hradecky, George // Pharmaceutical Representative;May2005, Vol. 35 Issue 5, p3 

    Explores challenges facing pharmaceutical representatives in the United States. Criticism of the profession; Relationship with patients and physicians; Issues facing pharmaceutical representatives; Reasons why the pharmaceutical industry has a lot to be proud of.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics